Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia
Background: Chinese medicine (CM) is widely used for treating hyperlipidemias, especially in China. However, the heterogeneity of outcomes measured and reported across trials exacerbates the obstacles of evidence synthesis and effectiveness comparison. In this study, we develop a core outcome set (C...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.847101/full |
| _version_ | 1828364461831880704 |
|---|---|
| author | Geng Li Geng Li Ruxue Han Mingjun Lin Zehuai Wen Zehuai Wen Zehuai Wen Zehuai Wen Xiankun Chen Xiankun Chen Xiankun Chen Xiankun Chen |
| author_facet | Geng Li Geng Li Ruxue Han Mingjun Lin Zehuai Wen Zehuai Wen Zehuai Wen Zehuai Wen Xiankun Chen Xiankun Chen Xiankun Chen Xiankun Chen |
| author_sort | Geng Li |
| collection | DOAJ |
| description | Background: Chinese medicine (CM) is widely used for treating hyperlipidemias, especially in China. However, the heterogeneity of outcomes measured and reported across trials exacerbates the obstacles of evidence synthesis and effectiveness comparison. In this study, we develop a core outcome set (COS) for CM clinical trials for hyperlipidemia (COS-CM-Hyperlipidemia) to tackle the outcome issues.Methods: We generated candidate outcomes through a systematic review of interventional and observational studies of Chinese medicine for hyperlipidemias. The comprehensive search strategy was employed. Study selection and data collection were independently done by two researchers. We searched clinical trial registry platform to supplement the outcomes list extracted by systematic review. Then, we conducted a three-round Delphi survey. The stakeholders were hyperlipidemia patients, clinicians or researchers, in either CM/integrated Chinese or Western medicine, clinical pharmacy, clinical epidemiology or statisticians, or editors of important relevant journals and an ethicist. They used a 9-point Likert scale to determine how important they felt each outcome was in determining treatment success. A consensus meeting was held to confirm the final COS, based on the Delphi survey results.Results: We identified a total of 433 outcomes from 3,547 articles, and 28 outcomes from 367 registered trials. After standardization, we selected 71 outcomes to develop a preliminary outcome list for further consensus. After three Delphi survey rounds and one consensus meeting, the most important outcomes were determined for COS-CM-Hyperlipidemia. It included cardiovascular events, low-density lipoprotein cholesterol, risk of cardiovascular disease, total cholesterol, carotid intima-media thickness, high-density lipoprotein cholesterol, triglycerides, cerebrovascular events, adverse drug reactions and patient-reported symptoms.Conclusion: COS-CM-Hyperlipidemia may improve outcome reporting consistency in clinical trials. Further work is needed to explore the optimal methods for measuring these outcomes.Registration: The Core Outcome Measures in Effectiveness Trials Initiative (COMET): http://www.cometinitiative.org/studies/details/983. Registered on 25 April 2017. |
| first_indexed | 2024-04-14T05:17:08Z |
| format | Article |
| id | doaj.art-03598c45701a48c9a80505cc7fec5bcf |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-14T05:17:08Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-03598c45701a48c9a80505cc7fec5bcf2022-12-22T02:10:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-05-011310.3389/fphar.2022.847101847101Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for HyperlipidemiaGeng Li0Geng Li1Ruxue Han2Mingjun Lin3Zehuai Wen4Zehuai Wen5Zehuai Wen6Zehuai Wen7Xiankun Chen8Xiankun Chen9Xiankun Chen10Xiankun Chen11The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaKey Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaFoshan Hospital of Traditional Chinese Medicine, Foshan, ChinaGuangzhou Nansha Hospital of TCM, Guangzhou, ChinaThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaKey Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, ChinaThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaKey Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Global Public Health, Health Systems and Policy, Karolinska Institute, Stockholm, SwedenBackground: Chinese medicine (CM) is widely used for treating hyperlipidemias, especially in China. However, the heterogeneity of outcomes measured and reported across trials exacerbates the obstacles of evidence synthesis and effectiveness comparison. In this study, we develop a core outcome set (COS) for CM clinical trials for hyperlipidemia (COS-CM-Hyperlipidemia) to tackle the outcome issues.Methods: We generated candidate outcomes through a systematic review of interventional and observational studies of Chinese medicine for hyperlipidemias. The comprehensive search strategy was employed. Study selection and data collection were independently done by two researchers. We searched clinical trial registry platform to supplement the outcomes list extracted by systematic review. Then, we conducted a three-round Delphi survey. The stakeholders were hyperlipidemia patients, clinicians or researchers, in either CM/integrated Chinese or Western medicine, clinical pharmacy, clinical epidemiology or statisticians, or editors of important relevant journals and an ethicist. They used a 9-point Likert scale to determine how important they felt each outcome was in determining treatment success. A consensus meeting was held to confirm the final COS, based on the Delphi survey results.Results: We identified a total of 433 outcomes from 3,547 articles, and 28 outcomes from 367 registered trials. After standardization, we selected 71 outcomes to develop a preliminary outcome list for further consensus. After three Delphi survey rounds and one consensus meeting, the most important outcomes were determined for COS-CM-Hyperlipidemia. It included cardiovascular events, low-density lipoprotein cholesterol, risk of cardiovascular disease, total cholesterol, carotid intima-media thickness, high-density lipoprotein cholesterol, triglycerides, cerebrovascular events, adverse drug reactions and patient-reported symptoms.Conclusion: COS-CM-Hyperlipidemia may improve outcome reporting consistency in clinical trials. Further work is needed to explore the optimal methods for measuring these outcomes.Registration: The Core Outcome Measures in Effectiveness Trials Initiative (COMET): http://www.cometinitiative.org/studies/details/983. Registered on 25 April 2017.https://www.frontiersin.org/articles/10.3389/fphar.2022.847101/fullhyperlipidemiacore outcome setChinese medicinesystematic reviewdelphi survey |
| spellingShingle | Geng Li Geng Li Ruxue Han Mingjun Lin Zehuai Wen Zehuai Wen Zehuai Wen Zehuai Wen Xiankun Chen Xiankun Chen Xiankun Chen Xiankun Chen Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia Frontiers in Pharmacology hyperlipidemia core outcome set Chinese medicine systematic review delphi survey |
| title | Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia |
| title_full | Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia |
| title_fullStr | Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia |
| title_full_unstemmed | Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia |
| title_short | Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia |
| title_sort | developing a core outcome set for clinical trials of chinese medicine for hyperlipidemia |
| topic | hyperlipidemia core outcome set Chinese medicine systematic review delphi survey |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.847101/full |
| work_keys_str_mv | AT gengli developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT gengli developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT ruxuehan developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT mingjunlin developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT zehuaiwen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT zehuaiwen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT zehuaiwen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT zehuaiwen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT xiankunchen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT xiankunchen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT xiankunchen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia AT xiankunchen developingacoreoutcomesetforclinicaltrialsofchinesemedicineforhyperlipidemia |